Monopar Therapeutics (MNPR) Stock Forecast, Price Target & Predictions

MNPR Stock Forecast

Monopar Therapeutics stock forecast is as follows: an average price target of $22.00 (represents a 21.61% upside from MNPR’s last price of $18.09) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

MNPR Price Target

The average price target for Monopar Therapeutics (MNPR) is $22.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $22.00 to $22.00. This represents a potential 21.61% upside from MNPR's last price of $18.09.

MNPR Analyst Ratings

Buy

According to 3 Wall Street analysts, Monopar Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for MNPR stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Monopar Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 11, 2024	Sean Lee	H.C. Wainwright	$22.00	$15.81	39.15%	21.61%

Row per page

Go to

The latest Monopar Therapeutics stock forecast, released on Nov 11, 2024 by Sean Lee from H.C. Wainwright, set a price target of $22.00, which represents a 39.15% increase from the stock price at the time of the forecast ($15.81), and a 21.61% increase from MNPR last price ($18.09).

Monopar Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	1	1	1
Avg Price Target	$22.00	$22.00	$22.00
Last Closing Price	$18.09	$18.09	$18.09
Upside/Downside	21.61%	21.61%	21.61%

In the current month, the average price target of Monopar Therapeutics stock is $22.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 21.61% increase as opposed to Monopar Therapeutics's last price of $18.09. This month's average price target is down 0.00% compared to last quarter, and down 0.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 11, 2024	Rodman & Renshaw	-	Buy	Initialise
Aug 12, 2024	H.C. Wainwright	Buy	Buy	Hold
Jan 28, 2021	Roth Capital	-	Buy	Initialise

Row per page

Go to

Monopar Therapeutics's last stock rating was published by Rodman & Renshaw on Oct 11, 2024. The company Initialise its MNPR rating from "null" to "Buy".

Monopar Therapeutics Financial Forecast

Monopar Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
Revenue	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-
# Analysts	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-

Monopar Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. MNPR's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Monopar Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-

undefined analysts predict MNPR's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Monopar Therapeutics's previous annual EBITDA (undefined) of $NaN.

Monopar Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-
Net Income	-	-	-	-	-	-	-
Avg Forecast	$-42.48M	$-39.78M	$-36.14M	$-33.56M	$-29.22M	$-35.03M	$-1.75M
High Forecast	$-42.48M	$-39.78M	$-36.14M	$-33.56M	$-26.48M	$-35.03M	$-1.75M
Low Forecast	$-42.48M	$-39.78M	$-36.14M	$-33.56M	$-31.05M	$-35.03M	$-1.75M
Surprise %	-	-	-	-	-	-	-

Monopar Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. MNPR's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Monopar Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-
SG&A	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-

Monopar Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to MNPR last annual SG&A of $NaN (undefined).

Monopar Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-
EPS	-	-	-	-	-	-	-
Avg Forecast	$-1.21	$-1.13	$-1.03	$-0.95	$-0.83	$-0.99	$-0.50
High Forecast	$-1.21	$-1.13	$-1.03	$-0.95	$-0.75	$-0.99	$-0.50
Low Forecast	$-1.21	$-1.13	$-1.03	$-0.95	$-0.88	$-0.99	$-0.50
Surprise %	-	-	-	-	-	-	-

According to undefined Wall Street analysts, Monopar Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to MNPR previous annual EPS of $NaN (undefined).

Monopar Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
PMVP	PMV Pharmaceuticals	$1.61	$18.00	1018.01%	Buy
ANTX	AN2 Therapeutics	$1.00	$8.75	775.00%	Buy
PEPG	PepGen	$4.12	$29.50	616.02%	Buy
MOLN	Molecular Partners	$5.33	$29.00	444.09%	Buy
AVTE	Aerovate Therapeutics	$2.53	$13.00	413.83%	Hold
ANEB	Anebulo Pharmaceuticals	$1.59	$6.00	277.36%	Buy
ACRV	Acrivon Therapeutics	$6.96	$21.83	213.65%	Buy
MLYS	Mineralys Therapeutics	$11.48	$30.00	161.32%	Buy
RZLT	Rezolute	$5.29	$13.50	155.20%	Buy
ADAG	Adagene	$2.16	$5.00	131.48%	Buy
DMAC	DiaMedica Therapeutics	$4.01	$8.33	107.73%	Buy
PHVS	Pharvaris	$20.35	$39.67	94.94%	Buy
MNPR	Monopar Therapeutics	$18.09	$22.00	21.61%	Buy

MNPR Forecast FAQ

Is Monopar Therapeutics a good buy?

Yes, according to 3 Wall Street analysts, Monopar Therapeutics (MNPR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of MNPR's total ratings.

What is MNPR's price target?

Monopar Therapeutics (MNPR) average price target is $22 with a range of $22 to $22, implying a 21.61% from its last price of $18.09. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Monopar Therapeutics stock go up soon?

According to Wall Street analysts' prediction for MNPR stock, the company can go up by 21.61% (from the last price of $18.09 to the average price target of $22), up by 21.61% based on the highest stock price target, and up by 21.61% based on the lowest stock price target.

Can Monopar Therapeutics stock reach $30?

MNPR's average twelve months analyst stock price target of $22 does not support the claim that Monopar Therapeutics can reach $30 in the near future.

What is Monopar Therapeutics's current price target trend?

1 Wall Street analyst forecast a $22 price target for Monopar Therapeutics (MNPR) this month, up 21.61% from its last price of $18.09. Compared to the last 3 and 12 months, the average price target increased by 21.61% and increased by 21.61%, respectively.

What are Monopar Therapeutics's analysts' financial forecasts?

Monopar Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-65.999M (high $-63.26M, low $-67.825M), average SG&A $0 (high $0, low $0), and average EPS is $-2.325 (high $-2.247, low $-2.377). MNPR's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-152M (high $-152M, low $-152M), average SG&A $0 (high $0, low $0), and average EPS is $-4.317 (high $-4.317, low $-4.317).